CUMBERLAND PHARMACEUTICALS INC

Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing, and commercializing prescription medications for hospital acute care, gastroenterology, and oncology markets. The company's marketed portfolio includes Acetadote for acetaminophen poisoning treatment, Caldolor for pain and fever management, Kristalose as a prescription laxative, Sancuso for chemotherapy-related nausea and vomiting prevention, Vaprisol for hyponatremia treatment, and Vibativ for serious bacterial infections including hospital-acquired and ventilator-associated pneumonia and complicated skin infections.

The company maintains a pipeline of investigational programs, including ifetroban, which has completed Phase II trials for cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, and portal hypertension, and is currently in Phase II development for systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland operates with a lean organizational structure of 91 full-time employees and maintains operations in the United States and international markets.

Incorporated in Tennessee in 1999 and headquartered in Nashville, the company operates as a publicly traded entity on the Nasdaq exchange. Cumberland's business model centers on acquiring established specialty pharmaceutical products with limited competition and developing early-stage drug candidates targeting niche therapeutic areas in hospital and specialty care settings.